Reflections from ASRS - Scorecard - MDSpire

Reflections from ASRS

Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.

  • By

  • Diana V. Do, MD

  • September 1, 2025

  • 3 min

Share

Clinical Scorecard: Reflections from ASRS

At a Glance

CategoryDetail
ConditionRetinal disorders including uveitis, ocular oncology, and pediatric retina
Key MechanismsEmerging treatments and technologies including IL-6 inhibitors and AI in ROP care
Target PopulationPatients with vision-threatening retinal disorders
Care SettingOphthalmology clinics and surgical settings

Key Highlights

  • Importance of timely diagnosis and management of vasoproliferative tumors
  • Advancements in AI for standardizing ROP diagnosis and monitoring
  • Current investigations into IL-6 inhibitors for noninfectious uveitis
  • Challenges and efficacy of the port delivery system (PDS) for ranibizumab
  • Adaptation of PDS for novel therapeutics in retinal diseases

Guideline-Based Recommendations

Diagnosis

  • Utilize advanced imaging and AI systems for accurate retinal diagnoses
  • Timely diagnosis of uveal melanoma and vasoproliferative tumors is crucial

Management

  • Consider IL-6 inhibitors for noninfectious uveitis
  • Incorporate PDS for treatment of neovascular age-related macular degeneration

Monitoring & Follow-up

  • Implement AI tools for monitoring progression of retinopathy of prematurity

Risks

  • Be aware of safety setbacks associated with PDS post-approval

Patient & Prescribing Data

Patients with retinal disorders requiring innovative treatment options

Emerging therapies and technologies are being explored to enhance patient outcomes

Clinical Best Practices

  • Stay updated on the latest innovations in retinal treatments
  • Engage in continuous education through conferences and peer discussions
  • Accurately code clinical findings to support medical necessity for treatments

Related Resources & Content

Original Source(s)

Reflections from ASRS

  • by Diana V. Do, MD

  • September 1, 2025

Related Content

Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Uveitis Coding Considerations